Skip to main content
Advertisement
Advertisement

IBIO

IBIO logo

iBio, Inc. Common Stock

1.20
USD
Sponsored
-0.01
-0.41%
Sep 14, 15:59 UTC -4
Closed
exchange

After-Market

1.23

+0.03
+2.17%

IBIO Earnings Reports

Positive Surprise Ratio

IBIO beat 8 of 20 last estimates.

40%

Next Report

Date of Next Report
Nov 10, 2026
Estimate for Q1 27 (Revenue/ EPS)
$25.50K
/
-$0.07
Implied change from Q4 26 (Revenue/ EPS)
--
/
--
Implied change from Q1 26 (Revenue/ EPS)
-74.50%
/
-36.36%

iBio, Inc. Common Stock earnings per share and revenue

On Aug 28, 2026, IBIO reported earnings of -0.07 USD per share (EPS) for Q4 26, missing the estimate of -0.06 USD, resulting in a -7.69% surprise. Revenue reached --, compared to an expected 58.28 thousand, with a -100.00% difference. The market reacted with a -2.86% price change (close before vs. close after earnings).
Looking ahead to Q1 27, 3 analysts forecast an EPS of -0.07 USD, with revenue projected to reach 25.50 thousand USD, implying an increase of 0.00% EPS, and -- of --% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Attovia Therapeutics, Inc. Common Stock
Report Date
Sep 02, 2026 For Q2 26
Estimate
-$2.78
Actual
-$4.88
Surprise
-75.25%
logo
Scribe Therapeutics Inc. Common Stock
Report Date
Sep 02, 2026 For Q2 26
Estimate
-$3.03
Actual
-$2.62
Surprise
+13.59%
logo
enGene Therapeutics Inc. Common Stock
Report Date
Sep 08, 2026 For Q3 26
Estimate
-$0.43
Actual
-$0.47
Surprise
-7.16%
logo
Anixa Biosciences, Inc.
Report Date
Sep 09, 2026 For Q3 26
Estimate
-$0.08
Actual
-$0.08
Surprise
+8.78%
logo
Immutep Limited - ADR
Report Date
Sep 01, 2026 For Q4 26
Estimate
$0.00
Actual
-$0.02
Surprise
-2,500.00%
logo
Alzamend Neuro, Inc. Common Stock
Report Date
Sep 10, 2026 For Q1 27
Estimate
-$0.57
Actual
-$0.68
Surprise
-19.05%
FAQ
For Q4 2026, iBio, Inc. Common Stock reported EPS of -$0.07, missing estimates by -7.69%, and revenue of $0.00, -100% below expectations.
The stock price moved down -2.86%, changed from $1.40 before the earnings release to $1.36 the day after.
The next earning report is scheduled for Nov 10, 2026.
Based on 3 analysts, iBio, Inc. Common Stock is expected to report EPS of -$0.07 and revenue of $25.50K for Q1 2027.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement